新型冠狀病毒肺炎（COVID-19）是一種由嚴重急性呼吸綜合征冠狀病毒2（SARS-CoV-2）引起的新型傳染病。SARS-CoV-2具有極強的傳染性,因此在引發(fā)流行病后又使其迅速升級為全球大流行,至今仍在部分國家迅速傳播。在COVID-19的感染者中,存在腫瘤等慢性病或伴有相關合并癥的患者預后往往較差。同時,由于惡性血液腫瘤患者長期處于免疫抑制狀態(tài),往往感染風險更高且預后更差,所以十分值得我們關注。這篇綜述歸納并分析了惡性血液腫瘤患者合并COVID-19后的臨床表現(xiàn)。此外,歸納了疫情期間惡性腫瘤的管理策略和感染后的綜合干預措施,旨在為臨床提供指導。 

【文章頁數(shù)】：19 頁

【文章目錄】：
1 Introduction
2 Regional reports of SARS-Co V-2 infections in patients with HMs
3 Specific clinical manifestations,radiologic patterns,and laboratory findings in patients with COVID-19 and HMs
    3.1 Clinical manifestations
    3.2 Radiologic findings
    3.3 Laboratory tests
4 Clinical diagnostic criteria and differential diagnoses of patients with COVID-19 and HMs
5 General management strategies for patients with HMs during the COVID-19 pandemic
    5.1 Considerations for hospital admission procedures
    5.2 Considerations for hematological therapeutic regimens
        5.2.1 Chemotherapy
        5.2.2 Immunotherapy
        5.2.3 Hematopoietic stem cell transplantation
        5.2.4 Recommendations for regimen adjustments
            5.2.4. 1 Acute leukemia
            5.2.4. 2 Chronic leukemia
            5.2.4. 3 Lymphoma
            5.2.4. 4 Multiple myeloma
    5.3 Considerations for follow-up plans
6 Comprehensive intervention strategies for patients with COVID-19 and preexisting HMs
7 Conclusions
Contributors
Compliance with ethics guidelines


【參考文獻】：
期刊論文
[1]2019冠狀病毒病流行期間兒童血液腫瘤病房規(guī)范化管理建議[J]. 邱奕寧,李力,吳小艷,金潤銘.  中國當代兒科雜志. 2020(03)



本文編號：3678608